Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a

Vincent Rijckborst, Bettina E. Hansen, Peter Ferenci, Maurizia R. Brunetto, Fehmi Tabak, Yilmaz Cakaloglu, A. Galeota Lanza, Vincenzo Messina, Claudio Iannacone, Benedetta Massetto, Loredana Regep, Massimo Colombo, Harry L A Janssen, Pietro Lampertico

Research output: Contribution to journalArticlepeer-review

Abstract

Background & Aims: It was recently demonstrated that none of the hepatitis B e antigen (HBeAg)-negative patients without any serum hepatitis B surface antigen (HBsAg) decline and with

Original languageEnglish
Pages (from-to)1006-1011
Number of pages6
JournalJournal of Hepatology
Volume56
Issue number5
DOIs
Publication statusPublished - May 2012

Keywords

  • HBV genotype
  • HBV therapy
  • Immunomodulator
  • Nucleos(t)ide analogues
  • Peginterferon
  • Quantitative HBsAg

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a'. Together they form a unique fingerprint.

Cite this